TICKERNERD
Menu
EBSEBSHealthcare · Drug Manufacturers - Specialty & Generic

EBS Stock Forecast: Emergent BioSolutions, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$7.07
+1.73% on the day

The 3 Wall Street analysts covering Emergent BioSolutions, Inc. hold a median 12-month price target of $11 — +55.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$356.3M
Ticker Nerd rank
87 / 100
Median analyst target
$11
Analysts covering
3
Revenue$226.8M+74.1% y/y
Operating income$66.2M
Net income−$180.2M
Free cash flow$54.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.1%
1M
+13.8%
YTD
−42.8%
1Y
−28.7%
From 52W high
−49.1%
From 52W low
+58.9%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EBS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Emergent BioSolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Accruals
99
Issuance
98
Quality
95
Size
58
Revisions
49
Growth
35
Momentum
31
Volatility
14

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EBS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EBS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26EBSHigh $12Median $11Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy0 Hold1 Sell
Low $10Median $11High $12

The green dot is the last close — the median target sits +55.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$10
21 Aug 2026JP MorganReinstatesUnderweight—
10 Aug 2026HC Wainwright & Co.MaintainsBuy$12 → $10
10 Aug 2026HC Wainwright & Co.MaintainsBuy—
9 Mar 2026HC Wainwright & Co.MaintainsBuy—
9 Mar 2026HC Wainwright & Co.MaintainsBuy$15 → $12
16 Dec 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
21 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024HC Wainwright & Co.InitiatesBuy—
7 Nov 2024BenchmarkMaintainsBuy—
13 Sept 2024Rodman & RenshawReiteratesBuy—
22 Aug 2024Rodman & RenshawInitiatesBuy—
16 Aug 2024BenchmarkReiteratesBuy—
9 Aug 2024BenchmarkReiteratesBuy—
3 July 2024BenchmarkReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EBS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EBS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Emergent BioSolutions, Inc. returned −28.7% against +17.7% for the S&P 500, dividends included.

EBS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26EBSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EBS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−62.1%
Analysts raising
1
Analysts cutting
0
Fundamentals

Emergent BioSolutions, Inc. (EBS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.6×

Cheaper than 60% of US stocks

Price / sales
0.5×

Cheaper than 84% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
3.5×

Cheaper than 55% of US stocks

Growth & margins
Revenue growth (YoY)
66.3%

Higher than 90% of US stocks

Earnings growth (YoY)
74.1%

Higher than 80% of US stocks

Gross margin
57.2%

Higher than 70% of US stocks

Operating margin
28.3%

Higher than 86% of US stocks

Net margin
−23.0%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−40.3%

Higher than 24% of US stocks

Return on assets
6.9%

Higher than 85% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Emergent BioSolutions, Inc. (EBS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Emergent BioSolutions, Inc. has a market value of $356.3M and an enterprise value of $819.7M.

  • Revenue in the twelve months to 30 June 2026: $742.3M. The latest quarter grew 66.3% year on year.

  • Net income over the same four quarters: −$176.8M, a −23.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.55.

  • Free cash flow in the twelve months to 30 June 2026: $85.9M.

  • Emergent BioSolutions, Inc. spent $36.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 51.3M.

  • Trailing P/E: 8.6×; forward P/E: 6.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Emergent BioSolutions, Inc. employs 900 people — $825K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

EBS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
EBSEmergent BioSolutions, Inc.$356.3M
87
CGCCanopy Growth Corp.$402.5M
42
GLASGlass House Brands, Inc.$427.3M
37
ACBAurora Cannabis, Inc.$297.3M
59
BIOABioAge Labs, Inc.$279.1M
37
TKNOAlpha Teknova, Inc.$469.1M
96
KMDAKamada Ltd.$475.7M
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Emergent BioSolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EBS news & analysis

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?

Zacks Investment Research · 6 Oct 2026neutral

Emergent BioSolutions (EBS) rose 14.4% on higher-than-average trading volume in its last session. However, the latest trend in earnings estimate revisions may not support further near-term upside for the stock.

Why it matters — EBS watchers would care because the stock's recent price surge may not be backed by improving earnings estimates, suggesting limited near-term momentum.

Russian plague outbreak could boost these under-the-radar pharma stocks

Invezz · 5 Oct 2026positive

A researcher at a Siberian anti-plague facility in the Irkutsk region was fatally exposed to Yersinia pestis, causing pneumonic plague, prompting Russian officials to quarantine several regional hospitals and isolate nearly 200 contacts.

Why it matters — Emergent BioSolutions develops medical countermeasures against biological threats, so a plague outbreak could draw attention to its biodefense and public-health products.

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

GlobeNewsWire · 15 Sept 2026positive

Emergent BioSolutions announced it will host a ribbon cutting ceremony on September 16 at its Canton, Massachusetts facility to celebrate the restart and growth of manufacturing at the site and the company's investment in advanced biopharmaceutical manufacturing in the Commonwealth.

Why it matters — EBS watchers would care because the restart and expansion of the Canton manufacturing facility signals renewed operational capacity and long-term investment in Emergent's production footprint.

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

GlobeNewsWire · 3 Sept 2026positive

Emergent BioSolutions completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, spending about $68 million in cash at an average price of 90.6% of face value. The outstanding aggregate principal balance of the notes has been reduced to approximately $364.7 million following the transaction.

Why it matters — The repurchase reduces Emergent's outstanding debt and future interest obligations at a discount to face value, strengthening its balance sheet and liquidity position.

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GlobeNewsWire · 1 Sept 2026positive

Emergent BioSolutions announced a contract modification valued at approximately $24 million from BARDA to supply CYFENDUS® anthrax vaccine for U.S. anthrax preparedness efforts. The award supports ongoing public health and national security preparedness against the anthrax biological threat.

Why it matters — This new government funding bolsters Emergent's medical countermeasures business with an additional revenue stream tied to a key federal partner.

FAQ

Frequently asked questions about EBS stock

What is the EBS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Emergent BioSolutions, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EBS stock a buy right now?

Of the 3 analysts covering Emergent BioSolutions, Inc., 2 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Emergent BioSolutions, Inc. 87 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EBS?

As at 6 Oct 2026, Emergent BioSolutions, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will EBS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +55.6% from the last close, and Ticker Nerd's factor model ranks Emergent BioSolutions, Inc. 87 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EBS stock forecast for 2030?

No analyst covering Emergent BioSolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EBS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $12 over the next 12 months.

How has EBS stock performed over the past year?

Emergent BioSolutions, Inc. returned -28.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Emergent BioSolutions, Inc. do?

Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats.

What is the latest news on EBS?

The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?". Emergent BioSolutions (EBS) rose 14.4% on higher-than-average trading volume in its last session. However, the latest trend in earnings estimate revisions may not support further near-term upside for the stock.

Company

About Emergent BioSolutions, Inc.

Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats. Its current business centers on medical countermeasures and specialty products, including public health protection tools used by government agencies, healthcare providers, and other institutional customers. The company’s portfolio includes commercial products, medical countermeasure products, and services, with an emphasis on areas such as opioid overdose reversal, smallpox and anthrax preparedness, and contract development and manufacturing support. Emergent BioSolutions plays a specialized role in the healthcare and biodefense markets by supplying products and services designed to support emergency readiness and public health response across the United States and international markets.

CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph. · 900 employees · United States · https://www.emergentbiosolutions.com